CG-806 for Leukemia and Non-Hodgkin's Lymphoma

Recruiting in Palo Alto (17 mi)

+29 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Aptose Biosciences Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?

This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas who have failed or are intolerant to two or more lines of established therapy or for whom no other treatment options are available.

Research Team

Rafael Bejar, MD, PhD

Principal Investigator

Aptose Biosciences Inc.

Eligibility Criteria

This trial is for adults over 18 with chronic lymphocytic leukemia, small lymphocytic lymphoma, or Non-Hodgkin's Lymphomas who haven't responded to at least two treatments. They must be able to swallow pills and have a life expectancy of more than 2 months. People with severe immune conditions, blood clotting issues, uncontrolled brain disease or anemia are not eligible.

Inclusion Criteria

You are expected to live for at least 2 more months.

My blood counts are within normal ranges, unless due to my condition.

I am 18 years old or older.

See 3 more

Exclusion Criteria

I do not have uncontrolled brain or spinal cord disease, autoimmune blood disorders, or severe metabolic issues.

You have taken any experimental medication within 2 weeks before starting this study.

I have GVHD and need drugs to suppress my immune system.

See 1 more

Treatment Details

Interventions

CG-806 (Tyrosine Kinase Inhibitor)

Trial OverviewThe study tests the safety and effectiveness of CG-806 taken orally by patients with certain types of blood cancers that have not improved after previous therapies or when no other treatment options exist.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Dose Escalation and ExpansionExperimental Treatment1 Intervention

CG-806 will be given orally in ascending doses in patients with relapsed or refractory CLL/SLL or Non-Hodgkin's Lymphomas (escalation cohort), until the maximum tolerated dose or recommended dose is reached. Followed by up to 100 patients enrolled in the expansion cohort at the recommended dose.